NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1527.00 -15.20 (-0.99%)

260.9K NSE+BSE Volume

NSE 23 Sep, 2025 11:02 AM (IST)

123,345.8

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Cipla Ltd.

07 Aug 2019

1527.00

-0.99%

Cipla

Buy: Cipla Ltd.

Sharekhan

Q1FY2020 saw Cipla report strong operational numbers. Sales growth remained tepid at 1.3% y-o-y to Rs. 3,989 crore (below our estimates). Operating profit grew by a strong 24.5% y-o-y to Rs. 904.6 crore. OPM improved by 424 bps y-o-y to 22.7% (vs. our expectation of 21.5%). Adjusted profit for the quarter reported a strong growth of 21% y-o-y to Rs 470 .7 crore. During the quarter, US business witnessed a whopping 67% y-o-y jump on account of limited competition product gSensipar (which shall normalise from Q2FY2020 due to increased competition)....

Cipla Ltd.'s price crossed below 30Day SMA today

Cipla Ltd.

07 Aug 2019

1527.00

-0.99%

Cipla (BUY): Core EBITDA miss; recovery ahead

Buy: Cipla Ltd.

Target

BOB Capital Markets Ltd.

Q1 was subdued and had multiple moving parts: (1) reduction in India GRx business by Rs 2bn, (2) Rs 1.6bn sales deferral in India Rx + EM market, (3) gSensipar sales worth US$40mn, and (4) weak ROW commentary.

Cipla Ltd.'s price crossed below 50Day SMA today

Cipla Ltd.

28 May 2019

1527.00

-0.99%

Cipla Ltd. - Result Update - 28 May 2019

Results Update: Cipla Ltd.

Way2Wealth

Cipla reported a strong set of numbers with revenue/EBITDA/PAT growth of 19%/75%/54% (adjusted for an exceptional item in Q4FY18). Revenue growth during the quarter was driven by India (11%), North America (53%), and Europe (73%) business. For FY19, revenue grew by 9% aided by India (7%) and North America (29%) markets while African tendering arm remained under pressure. EBITDA grew by 75% YoY to `972 Cr during the quarter. EBITDA margins for the quarter stood at 22%, expansion of ~700bps YoY. Net profit was reported at `358 Cr for the quarter....

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

28 May 2019

1527.00

-0.99%

Cipla Limited

Results Update: Cipla Ltd.

SMC online

Cipla Ltd.'s price crossed below 30Day SMA today

Cipla Ltd.

27 May 2019

1527.00

-0.99%

Cipla: Q4FY19 Result Review

Accumulate: Cipla Ltd.

Target

IDBI Capital

Cipla reported stronger results in Q4 and beat our Revenue/EBIDTA and PAT estimates by 7%/22%/40%, thanks to launch of gSensipar during March'19 and ramp up in other products. gSensipar has been launched at risk' and it contributed $40mn of revenue, which came as a positive surprise. The management has guided for double digit growth in most of geographies and re-iterated to launch at least one limited competition product in US during each quarter. The supply constraints it faced during past few quarters are resolved now and therefore the growth momentum is likely to be stable. We expect a revenue/PAT CAGR of 12%/16% over FY19-21E. We have revised our price...

Cipla Ltd.'s price crossed below 30Day SMA today

Cipla Ltd.

23 May 2019, 11:00AM

1527.00

-0.99%

Cipla (4QFY19): Temporary hurdles overcome. Maintain BUY

Buy: Cipla Ltd.

Target

HDFC Securities

The worries related to supply constraints, Iran/Yemen geopolitical uncertainty, and raw material prices are either priced in or resolved, in our view. Moreover, Cipla has surpassed its US business guidance of US$ 125mn run rate in 4QFY19. We believe it was crucial for Cipla to cross the US$ 120mn revenue mark to breakeven in the segment. Going into FY20/21E, we expect the US momentum will continue to drive profitability, while launches like gProventil could provide a further boost. Overall, we model 12/16/24% CAGR in revenue/EBITDA/PAT over FY19-21E. At CMP the stock is trading at 26/20x FY20/21E P/E, which is a premium to generic peers. The premium is justified due to a richer mix. We maintain BUY on CIPLA following a modest beat to our estimates. Our TP is revised at Rs 625/sh (22x FY21E EPS). We believe most of the concerns are allayed.

Cipla Ltd. is trading below its 30 day SMA of 1561.8

Cipla Ltd.

23 May 2019, 12:00AM

1527.00

-0.99%

Cipla

Hold: Cipla Ltd.

Target

ICICI Securities Limited

Q4FY19 revenues grew 19.1% YoY to | 4404 crore (I-direct estimate: | 3783 crore) mainly due to 69% YoY growth in the US to | 1143 crore (I-direct estimate: | 814.3 crore) led by launched of gSensipar at risk. Domestic revenues grew 10.9% YoY to | 1500 crore (I-direct estimate: | 1420.7 crore). EBITDA margins improved 676 bps YoY to 21.8% (I-direct estimate: 16.1%) due to mainly due to gSensipar launch. EBITDA grew 72.6% YoY to | 961 crore (I-direct estimate: | 607.9 crore). Net profit grew 60.9% YoY to | 383...

Cipla Ltd. is trading above its 200 day SMA of 1494.3

Cipla Ltd.

23 May 2019, 12:00AM

1527.00

-0.99%

First Light: Cipla, Astral Poly Technik, Somany Ceramics

Buy: Cipla Ltd.

Target

BOB Capital Markets Ltd.

Cipla reported a 13% beat on sales and EBITDA adjusting for gSensipar contribution in the US (US$ 40mn per management) during Q4. The beat was led by recovery in Europe & South Africa (private market), a higher US DTM mix and India growth. Cipla sees low litigation risk in the gSensipar at-risk launch and is guiding for an improved FY20, with double-digit growth in the US (incl. one inhaler launch). FY19 reported EPS is Rs 19 (Rs 2 from non-core...

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

23 May 2019, 12:00AM

1527.00

-0.99%

Cipla - 4QFY19 Result Update

Buy: Cipla Ltd.

Target

Reliance Securities

Cipla Ltd.'s price crossed below 50Day SMA today

Cipla Ltd.

22 May 2019, 12:00AM

1527.00

-0.99%

At-risk launches prove advantageous; on track to build a niche pipeline

Neutral: Cipla Ltd.

Target

Motilal Oswal

29% YoY to INR2b, driven by sales ramp-up in a few molecules and favorable FX. Domestic business outperformed industry in the key therapeutic areas, with growth of 11% YoY to INR15b (34% of sales). South African Global Access (SAGA) business, however, was flat YoY at INR8b. Limited-competition products drive profitability: Gross margin (GM) improved ~330bp YoY to 65.2%. EBITDA margin expanded at an even higher pace of ~680bp YoY to 21.8% due to a superior product mix and lower opex. Absolute EBITDA increased ~73% YoY to INR9.7b (our estimate: INR7.2b). R&D; spend was at 7% of...

Cipla Ltd.'s price crossed below 50Day SMA today

Is Cipla Ltd. worth buying?

623 Votes:

Buy 75.76%

Sell 13.96%

Hold 10.27%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf